TY - JOUR T1 - Protease inhibitors: Silver bullets for chronic hepatitis C infection? JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 213 LP - 222 DO - 10.3949/ccjm.79a.11082 VL - 79 IS - 3 AU - Naim Alkhouri AU - Nizar N. Zein Y1 - 2012/03/01 UR - http://www.ccjm.org/content/79/3/213.abstract N2 - Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population. ER -